Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Current Pharmaceutical Design|October 22, 2013
Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLCLudovica Ciuffreda, Ursula Cesta Incani, Linda S Steelman, et al.
Expert Opinion on Drug Discovery|October 4, 2013
Advances towards the design and development of personalized non-small-cell lung cancer drug therapySabrina Vari, Sara Pilotto, Marcello Maugeri-Saccà, et al.
Cell Death & Disease|March 24, 2026
AATF supports proliferation of glioblastoma cells by sustaining mitochondrial respiration through an NRF-1-dependent mechanismCristina Sorino, Stefano Di Giovenale, Italia Falcone, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 21, 2018
Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-MybSimona D'Aguanno, Elisabetta Valentini, Maria Grazia Tupone, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 20, 2022
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanomaRossella Loria, Valentina Laquintana, Stefano Scalera, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 11, 2018
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor modelsAnais Del Curatolo, Fabiana Conciatori, Ursula Cesta Incani, et al.
Journal of Molecular Medicine (Berlin, Germany)|January 5, 2012
The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanismsLudovica Ciuffreda, Cristina Di Sanza, Ursula Cesta Incani, et al.
International Journal of Molecular Sciences|July 29, 2025
HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic CombinationsItalia Falcone, Elena Giontella, Stefano Giuliani, et al.
Blood|September 8, 2025
Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapyTiziana Bruno, Maria Chiara Cappelletto, Clelia Cortile, et al.
Scientific Reports|February 22, 2017
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancerMichele Milella, Italia Falcone, Fabiana Conciatori, et al.
Pageof 4